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Search Continues for the Cause of Cervical Cancer
Does human papillomavirus
(HPV) really cause cervical
cancer? A profusion of research
articles has provided considerable evidence of a causal
relationship and has directed
widespread international
media attention to this issue.
However, a number of epidemiologically oriented researchers
Michele Follen Mitchell
like gynecologist Michele
Pollen Mitchell, M.D., take a more conservative stance.
"In some ways, molecular biologists and pathologists
are making the same mistakes that were made in the 1970s,
when we believed that herpes simplex virus-2 (HSV-2 )
was the cause," cautioned Mitchell, assistant professor of
gynecology at The University of Texas M. D. Anderson
Cancer Center. "We do consider HPV to be a risk factor,
but the mechanisms leading to cancer are far more
complex than the media would have patients believe."

The Link Between Cervical Cancer and a Sexually
Transmitted Disease
Media-attention has focused_on__the possibility that__Hl?_v,
usually a sexually transmitted disease, may be the carcinogenic agent for cervical cancer. This is a logical though
not necessarily true assumption, Mitchell said. Extensive
epidemiological research does pinpoint sexual behavior as
a risk factor for cervical intraepithelial neoplasia ( CIN),
carcinoma in situ ( CIS ), and invasive cervical carcinoma.
Among the women identified at a higher risk are those
who began intercourse at an early age, had many sexual
partners, did not use barrier contraception, and had been
exposed to sexually transmitted diseases. An increased risk
is conferred by the male partner if he has had a previous
partner with cervical cancer, many sexual partners, or
penile cancer, and possibly if he is uncircumcised.

For over 20 years, HSV-2 was thought to be that sexually transmissable agent. Researchers had found the virus
in thousands of cervical biopsies, and a few studies dem onstrated higher serum HSV-2 antibody levels in cervical
cancer patients than in controls. Those studies proved to
be flawed. In 1984, a study published by V. Vonka and
colleagues in Prague conclusively disproved that hypothesis; among 10,000 women, no differences were found in
HSV-2 antibody levels between patients with no cervical
abnormalities and those who developed CIN.

Admittedly, many researchers feel there is a much
stron-ger case for naming HPV the carcinugenic culprit,
based on epidemiologic and biologic data, Mitchell said.
HPV exposure is extremely widespread. Statistics
provided by The National Disease and Therapeutic
Index, a sampling of 10% of diseases treated by general
practitioners, indicate that HPV is greatly on the rise, and
condyloma acuminatum-a lesion caused by HPV-is the
most commonly diagnosed sexually transmitted viral
disease in both the United States and the United Kingdom.
Biologic studies have identified HPV in about 90% of
the cervical cancers examined; it has also been found in
many established cervical cancer cell lines. HPV-6 and
-11 a:re the most prevalent types in benign perinea!
continued on page 2
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condylomata, while HPV-16 and -18 are more often
found in vulvar, vaginal, cervical, and penile intraepithelial
neo~lasias and carcinomas. The presence of HPV types in
cervical squamous cell carcinomas has been demonstrated
in samples from the United States, Europe, Africa, Brazil,
and Panama.
Fu~ther biologic evidence, identified using DNA ploidy
an~lysis, has demonstrated that HPV-associated benign
lesions can progress to malignant disease. HPV-16 and
-18 possibly target the basal cells of squamous metaplastic
ep~thelium. Manifesting first as condylomatous atypia, the
lesion may then progress to CIN and later invasive cancer.
But the epidemiologic and biologic evidence collected
thus far, however suggestive, is fundamentally circumstan tial and is contradicted by other data, Mitchell said.
"We've seen dramatic increases in HPV of at least sixfold
over the last decade, but we're not seeing similar increases
in CIN or CIS, and we're certainly not seeing cervical
cancer increase; in fact, it's definitely decreasing. If HPV
is truly a causal mechanism, then we should see it causing
precancerous or invasive cancer rates to jump equally.
That's just not been the case."

Impr~ved Tests May Soon Provide the Key
While Pap tests, colposcopy, cervicography, and
magnification with a hand lens are extremely useful in
detecting and monitoring abnormal epithelium, they do
not differentiate the various viral types to provide the
information that researchers need. Other methods such
as improved immunohistochemical stains, polyme;ase
chain reaction, and antibody response level assays are
being developed.
'
More sophisticated methods of testing serum antib~dy response levels may also provide conclusive proof,
Mitchell said. In addition to elucidating the immune
response to HPV, serum antibody response levels would
allow researchers to prove whether HPV type-specific
antibodies are present in the blood of cervical cancer
patients. "We are on the forefront of an important period
when many questions will be answered," Mitchell feels.
(Thus far, however, Mitchell said that tests of HPV-16
and -18 antibody levels and corresponding epitope assays
in cancer patients have provided conflicting data.)

Epidemiologic Conclusions Slowed by
Flaws in Research

Epidemiologists Remain Unconvinced

For epidemiologists, the link between the two is
Sophisticated laboratory procedures can contribute
unproved. Causality requires that five criteria be estabto the data base, but only when used in a well- designed
lished: biologic credibility; strong indication of increased
study. Mitchell sees many flaws in studies she reads.
relative risk; a compatible time relationship; consistency
"We're seeing articles based on research that was simply
among many studies; and a dose-response relationship.
conducted too quickly before adequate information was
(Dose-response is not applicable as a criterion in studies of
gathered or before the long-term results were in. The
viruses, since number of exposures has no correlation with
really carefully done studies are slow-going. U nfortupresence of disease.)
nately, they are also expensive because of the facilities and
Though some may feel that the biologic evidence has
expertise necessary."
been ample, the other criteria have not been satisfied said
Generally, she finds that many studies lack in several
Mitchell, who listed several reasons for the lack of co~_
areas: careful consideration of the study population's
vincing data. For one, studies have been complicated by
characteristics ( failure to control for certain factors such
the fact that HPV is not considered a reportable disease
as age and sexual behavior, might weaken the stud;'s
by epidemiologic surveys, and CIN-a precancerous
findings); lack of rigid controls of certain clinical and
lesion-is not reported to cancer registries.
laboratory testing procedures; inadequate facilities or
Second, HPV may well be just one of several cofactors.
equipment; or improperly trained personnel. Statistical
The long latency period between HPV infection and the
analyses are often not as thorough as they should be.
development of cervical malignancy, Mitchell said, is one
"Medical schools simply do not provide much training in
~:ficant~cofactorSc1rrinvotvecbrtLake~ss--- - - re_s_e_ar~c;--h_d=e-=-=s=iag=-=n2-,'_' -=sh~e~sa~i~d:_'._-"~Y~e~t1p~hL_J_y~si~·c-_i:,ia~n~s~ar~e,__,e. ,_.,x~p~e~c-_l:'te--_1d~,L____
an average of 10 years for most of the precancerous cells
once they enter academic medicine, to also be researchto develop into cervical cancer.
ers." (Mitchell, a clinical gynecologist, is on the M. D.
Third, the difficulties involved in viral testing further
Anderson faculty as a lecturer in research design.)
complicate investigation efforts: A growing, maturing
For the past year, she has been preparing the framesquamous epithelial surface is required for the virus to
work of a case-control study designed to determine the
grow, so efforts to develop a papillomavirus culture
relative risk of HPV in causing cervical cancer. Her study,
system h~ve failed. As the surface becomes more neoplaswhich she will conduct through her clinical practice, will
tic, less virus can be extracted. The virus is thought to
analyze a var~ety of possible risk factors: nutrition, smoking,
incorporate into the DNA, making it impossible to obtain
sexual behavior, HPV type, and immunologic function.
viral bodies from the cytoplasm; DNA must therefore be
Assembling the appropriate study team members, identifying
extracted for study.
continued on page 7
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Breast Conservation Should Be the Patient's Choice
ments must be followed if the procedure is to be effective.
"First, the tumor has to be removed with adequate
margins of at least one centimeter in all directions, and it
is also preferable that the incision be directly over the
tumor to optimize the cosmetic result. Second, patients
also must undergo axillary node dissection, which is
necessary to stage disease, assess risk of recurrence, and
plan further treatment. Axillary dissection also minimizes
risk of nodal recurrence," Hohn said.

In the wake of mounting data,
many physicians have come to
believe that breast conservation is a legitimate treatment
option for patients with early
stage breast cancer. But some
physicians are reluctant to let
go of tradition and believe that
total mastectomy, the traditional treatment, is still the
David C. Hohn
treatment of choice.
For David C. Hohn, M.D., there is no controversy. He
regularly presents both options to eligible patients so that
they can choose. But Hohn, professor of surgery at The
University of Texas M. D. Anderson Cancer Center,
recognizes that treatment dogma is best changed not by
polemic but by data.

Panel Reaches Consensus
Last June, Hohn attended the National Institutes of
H ealth (NIH) Treatment of Early Stage Breast Cancer
Conference, which was convened to develop an official
position based on the most recent data. Hohn was a
member of a panel of 15 physicians and scientists who
were charged with drafting the NIH Consensus Development Panel statement. During the four-day conference,
data from prospective, randomized studies, some of which
had a decade or more of follow-up, were presented by
investigators from all over the world.
"We rigorously reviewed the data and then issued a
statement that we hoped had the capacity to clarify
misconceptions and change attitudes," Hohn said. "We
concluded that breast conservation should be considered
equivalent in terms of survival to any other treatment, and
in many cases cosmetic concerns make it preferable. If a
woman wants to keep her breast and is eligible for breast
conservation, she should have that option. Absolutely no
data indicate that survival is reduced by opting for breast
conservation instead of mastectomy."
It is important to stress, however, that the panel's
statement was not categorical. "Some panel members
wanted to come out and say that breast conservation is
the treatment of choice, but most of us agreed that it
isn't always. A variety of factors enter into the decision,"
Hohn said. "We simply said that breast conservation is
appropriate and often preferable. We did not say that
mastectomy is wrong."
Breast conservation therapy consists of local tumor
excision and axillary dissection followed by several weeks
of radiotherapy. Hohn stressed that two rigid require-

Contraindications to Breast Conserwation
Breast conservation, however, may not be an option
for patients with multifocal disease or extreme breast size
(very small or very large ). In regard to breast size, "local
excision has a much greater impact on the size of a small
breast, and radiotherapy may shrink it further still. With
current techniques, breast reconstruction after total
mastectomy can often achieve a cosmetically superior
result, so it may be best for these patients to elect total
mastectomy followed by breast reconstruction," Hohn said.
Breast conservation may also not be advisable for women
with very large breasts, since a higher radiation dose is
needed and mastectomy with reconstruction and contralateral reduction mammoplasty may yield superior cosmesis.
Even in the absence of contraindications, however,
physicians should not assume that patients will automatically choose breast conservation. Keeping the breast
is very important to most patients, but each patient
has specific circumstances that may lead her to choose
mast_ectomy. "Often it's logistics, often it's expense, often
it's fear ofradiotherapy," according to Hohn. "Physicians
should be very sensitive to patient preference."
continued on page 5
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The Uncertain Role of Adiuvant Systemic Therapy
How much should a patient
endure to improve the outcome of an already successful
therapy? Local therapy for
early stage breast cancer
cures 70% of patients. The
30% recurrence rate can be
decreased to 15-20% by
adjuvant systemic hormone
therapy or combination
Arna n U. Buzdar
chemotherapy, but are the
financial costs and the physical side effects worth the
10-15 % decrease in recurrence?
Last June, the National Institutes of Health (NIH)
Early Stage Breast Cancer Conference was convened in
Bethesda, Maryland to address several issues in early stage
(node-negative) breast cancer therapy. The Consensus
Development Panel-a task force of 15 conference
attendees-was made the voice of the conference. (See
"Breast Conservation Should Be the Patient's Choice" for
the panel's statement on breast conservation treatment.)
Their conclusion: Because of the treatment's toxicity, its
potential long-term side effects, and the restriction of its
benefit to a small percentage of the patient population,
systemic treatment cannot be recommended as the
treatment of choice for all patients. However, patients
should still have the option of choosing systemic therapy:
"The many unanswered questions in the adjuvant systemic
treatment of node-negative breast cancer make it imperative that all patients who are candidates for clinical trials
be offered the opportunity to participate," according to
the panel's report.

may far outweigh the potential benefit, whereas others
will want any chance, however slim, of reducing the
possibility ofrecurrence, according to Aman U. Buzdar,
M.D., who attended the NIH conference . Buzdar is
professor of medicine at The University of Texas M. D.
Anderson Cancer Center.
This issue is nothing new to physicians, and it usually
poses no difficulties when the physician knows that a
recommended treatment has a good chance of benefiting
the patient. But systemic therapy for early breast cancer
raises difficult questions. It is likely that one in ten patients
will benefit; it is certain that all ten patients will have to
deal with the treatment's toxicity.

More Prognostic Factors Needed
The crux of the problem is that current prognostic
factors cannot adequately define the degree of risk of
many subgroups. Reliable correlations have been found
for prognostic factors like tumor size, nuclear grade,
and histologic grade, and researchers are st udying the
potential of others like estrogen receptor St<.ltus, cell
proliferation rate, cathepsin D , the HER-2/neu oncogene,
and epidermal growth factor. These factors can help in
defining subgroups with high or low risk of recurrence,
Buzdar said, but a large proportion of patients fall into a
prognostic gray area.
"If we could accurately assess the risk of all subgroups,
we could be more confident recommending systemic
therapy for those with a statistically higher chance of
benefiting," Buzdar said. "Currently, we can accurately
assess risk only in a small subgroup of patients based
on three prognostic factors: tumor size, nuclear grade,
and histologic subtype. For patients with favorable
characteristics in all three categories (tumor less than one
centimeter in diameter, low nuclear grade, and tubular,
colloid, or papillary histologic subtype), we can safely
recommend that they not have systemic therapy, since
their chance of cure with just local therapy alone is very
0

•

Treatment Options: Tamoxifen or Chemotherapy
Patients with unfavorable or mixed prognostic factors,
on the other hand, have to make the difficult decision
of whether to receive tamoxifen therapy or receive
combination chemotherapy.
Both regimens have proved effective in reducing
recurrence rates, but premenopausal women or women
with estrogen receptor-negative tumors usually are not

No Accurate Assessment of Risk is Available
Underlying the panel's conclusion are two issues:
subjective assessment of risk and lack of precise prognostic
factors. For some patients, the risks of systemic therapy
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Breast Conservation

continued from page 3

Many Patients Still Choose Total Mastectomy

candidates for tamoxifen. The alteration of endocrine
function caused by tamoxifen has been tenuously linked
to endometrial can cer. Though not proved, this potential
side effect becomes all the more significant as treatment
periods are revised from two to five or ten years, as the
newer protocols now call for. (The growth-stimulatory
effects of estrogen are inhibited by tamoxifen, in effect
inactivating, though not killing, tumor cells. It is therefore thought that lo nger periods of treatment will reduce
recurrence by prolonging tumor cells' inactivation.)

"I still do more mastectomies than breast conservation,
and I'd like to believe I'm enlightened," Hohn said.
"Many patients listen to the pl usses (of breast conserva tion) and simply say no. They may not want to commit
themselves to four to five weeks of daily radiation treatments. I had a patient from central Texas who recently
opted for mastectomy. She said 'Look, I've got canning
to do, I've got kids at home to look after, and I'm going
to be working in the fall, and there's no radiation therapy
close by (her home town). I don't want to spend three
weeks recovering from surgery and spend five weeks
getting radiation in Houston."'
For this patient, the issues dealt with her responsibility
to her family, but cost can also be a reason for refusing
breast conservation. "For patients without insurance, cost
is a legitimate concern. The expense of local excision and
axillary dissection is about the same as that of mastectomy, but
then you add the cost of radiation, which is considerable."

Even without the possible connection between this
agent and endometrial cancer, the long-term administration of any drug raises legitimate concerns about its
effects. "We simply have no data on the long-term effects
of tamoxifen," Buzdar said.

More Survival Data Needed

A final issue to be resolved by future research is the
question of systemic therapy's effect on overall survival.
Hohn stressed that patients who choose breast conserReducing the rate of recurrence does not necessarily
vation must also make a commitment to long-term
improve final outcome. Over five years, disease may recur
surveillance. "If the patient chooses to retain her breast,
in fewer patients, but what if treatment is merely delaying,
she is obligated to monitor it carefully," Hohn said. "This
rather than preventing, recurrence?
is very important, especially in light of the fact that
It is clear that before a definitive statement on systemic
recurrent tumors in a treated breast may be harder to
--------ther-af)-y-E-a-B-e@----m-aa~F~s~afffi-@f-s-mu-s~t:er-mi-H-e-i-t-s--e---ff~E+--- - -~d~e~te~c~t~.~P~a=u=·e=n=t~s~n=e~e~d~t=o~u=n=d=e=r=
st=a=n=d.,_t=h=a=t'----'th
= e-=re
- -=---=is---=a- -s=
- m=a=l=-1__
on overall survival. Central to this objective is developing
possibility (probably less than one person in ten) oflocal
an array of prognostic factors that can accurately assess
recurrence, which will require mastectomy. But basically
risk. In the meantime, Buzdar said, "the best we can do is
the message should be positive: 90% of patients can keep
outline to the patient the risk and benefits of systemic
their breast without concern for jeopardizing survival."•
therapy." In the absen_ce of definitive data, the decision,
for most patients, is solely theirs. ■
Physicians who desire additional information may write David C .
Hohn, M.D., Department of General Surgery, Box 112, The University
of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard,
Houston, Texas 77030, or call (713) 792-6927.

Physicians who desire additional information may write Aman U.
Buzdar, M.D., Department of Medical Oncology, Box 78, The
University of Texas M. D . Anderson Cancer Center, 1515 Holcombe
Boulevard, Houston, Texas 77030, or call (713) 792 -2817.
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FNA Biopsy

continued from page 8

FNA an Excellent Alternative to Diagno tic
reening Thyr ·
1 b .

M. D. Anderson Fine eedle Aspiration clinic. Of th
1,995 cases, 1,147 were suitable for follow-up. H r tudy
focused on determining th pecificity ( the true p iti e )
and sensitivity (the true negative ) of cyt 1 gical te t f
tissue aspirated by F A. The pecificity, 99%, wa equi alent to that of most other tudi , but the n 1t1 1ty wa
96%-higher than that of mo t oth r r p rts (78- 96% )- and
the percentage of inconclusive ca e wa v ry 1 w (2. 7%).
"From a clinician' standpoint, the e valu are ry
significant," Sneige said. "High sen iti ity mean a
very low incidence of false negativ , and th ery lo
percentage of inconclusive result mean that few r
patients had to undergo surgery for biop y. Fal e po iti
reports occur even in the most experienced center .
However, the false positive rate with F A cytology i
similar to that reported with histological analy is of frozen
section samples (0-.4%), so F A cytology of brea t tis ue,
if performed by an experienced practitioner, is just a
good as the traditional technique."
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FNA Proves Accurate for B Cell Lymphoma
Sneige and her colleagues ha e also sho n that F A
cytology combined with immunocytochemical techniques
can be used to accurate! diagnose B cell I mphomas. Of
220 aspirates recently studied, 173 (79%) were correctly
diagnosed as one of seven subtypes of B cell lymphoma,
based on their expression of specific surface markers (Acta
Cytol 34:311- 323, 1990 ). The remaining samples were
classified as suspicious for lymphoma (7%), benign (10%),
or inadequate for diagnosis (4% ). (The F A diagnoses
were confirmed by histological analysis of tissue sections.)
"Immunocytochemical techniques ha e been applied to
histological analysis of lymph tissue for some time,"
Sneige said, "but their application to FNA cytology is
fairly new, so it was important to establish that F A
cytology is just as accurate and reliable."
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Sneige said that having a clinic dedicated solely to FNA
and staffed by pathologists has another advantage: The
pathologist has direct contact with the patient. This is
helpful when choosing the appropriate number of aspirates and the preparatory technique, and it allows the
pathologist to integrate the physical characteristics of the
tumor with its cytologic appearance.
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Patient Cont act Results in Better Assessments
"All these factors contribute to a more accurate assessment," Sneige said. "By feeling the mass and noting its
consistency ( tumor resistance) as the needle is inserted,
we can get an idea of whether the mass is malignant. The
characteristic 'gritty' consistency of malignant tumor, for
example, differs from the 'rubbery' feel of fibroadenoina.
This distinction can be useful if, for instance, we feel a
hard tumor in a patient whose first aspirate was negative
for malignancy. We'll therefore sample multiple areas of
tumor, since it's possible that the first aspirate might have
been taken from a sclerotic area devoid of tumor cells."
In addition to breast, lymph node, and thyroid tissue,
pathologists in the Fine Needle Aspiration clinic can
perform aspirations on any superficial mass. (For deep
tumors, aspirations are performed by a radiologist using
fluoroscopy, computed tomography, or sonography.)
Sneige said that over the years the clinic has added a
number of prognostic and diagnostic tests to its armamentarium (flow cytometry, estrogen and progesterone assays,
lymphoma surface marker studies) and hopes to offer
other tests in the future. Sneige added that use of the
clinic is not restricted to M. D. Anderson patients.
"Patients can be referred specifically for aspiration only,
so if a patient is being treated by his or her community
oncologist, the patient can use the clinic and still be
treated closer to home. For breast studies, however, we
advise that mammograms be performed before referral,
since aspirations can cause minor bleeding and distort
subsequent mammograms." ■

a valid study population, and developing all the components of the testing process has taken a year. The long-term
study-which involves over 400 patients-began entering
patients this fall. Similar studies are being conducted at
some of th~ major cancer research institutions, but more
tests throughout the United States are necessary to truly
determine the causes of cervical cancer, Mitchell said.
Mitchell recommends that physicians treat the ·
symptoms and conduct a biopsy to determine whether
the abormal cells are an indication of either preinvasive or
invasive cancer. She advises her patients that while there is
some evidence that HPV may contribute to both preclinical
and clinical cancer, she does not think that it is strong
enough across the board. "I don't get them worried
about it," she emphasizes. "I tell them simply that we
should follow the condition." ■

Physicians who desire additional information may write Nour Sneige,
M.D., Department of Pathology, Box 85, The University of Texas M. D.
Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas
77030, or call (713) 792-3140.

Physicians who desire additional information may write Michele Pollen
Mitchell, M.D., Department of Gynecology, Box 67, The University of
Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard,
Houston, Texas 77030, or call (713) 792-7462.

Published quarterly by the Department of Scientific Publications, Division of
Academic Affairs, The University of Texas M. D. Anderson Cancer Center,
1515 Holcombe Boulevard, Houston, Texas 77030. Made possible by a gift from
the late Mrs. Horry C. Wiess and grants from The University Cancer Foundation.
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Clinical Applications of
Fine Needle Aspiration Increase
Although cutting biopsy has
been the standard technique
for tissue diagnosis, fine needle
aspiration (F A) is rapidly
gaining popularity among
physicians as a less invasive
alternative. F A is most often
used to examine breast, lymph
node, and thyroid tissue, which
is aspirated through a 22- or
Nour Sneige
25-gauge needle. Diagnoses
can be obtained within 30 minutes of aspiration and are
just as accurate as those obtained from surgical biopsy.
FNA is less traumatic than surgery, is much less expensive, and requires no special preparations, except for local
anesthesia for patients who request it, according to
our Sneige, M.D., chief of the Fine eedle Aspiration
service and operatiOJ?.S director of Cytopathology at The
University of Texas M. D. Anderson Cancer Center.

Because of these ad an tag , F A i in r ingl b ing
used in the United States. But it fir t had t b pr , d
that cytological anal sis of F A-d ri d ti u
ju ta
accurate as histological anal i of ti u d ri d fr m
cutting biopsy. The primary diffi r n b tw n utting
biopsy and F A lies in the nature of th ampl and th
processing technique. With cutting biop
a larg r ti u
sample is obtained, which is th n fixed in formalin and
embedded in paraffin for histological staining. In F
however, the aspirated samples are smeared on lid
stained, and examined in a fev minutes. For the latt r an
experienced pathologist is needed for accurate interpr tation.
The data of Sneige and co orkers at the M. D.
Anderson Cancer Center and those of other in e tigators
around the country indeed confirm that c ological
analysis of tissue obtained b F A is just a accurate.
Sneige recent! anal zed the data from 1 995 breast
tissue aspirates performed between 1985 and 1989 in the
continued on page 6
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